Leiden, the Netherlands, Feb 2019 - Ncardia, a leader in stem cell technology solutions with R&D facilities in Leiden, launched today the DiscoverHIT Platform. Mayor Lenferink and Alderman Dirkse of Leiden visited the Ncardia facility last Friday, 1st February, to celebrate this milestone in implementing hiPSC-derived models early in the drug discovery pipeline for efficacy screening.
The DiscoverHIT Platform introduces true human disease biology into early drug discovery screening to enable selection of hit or lead series more likely to translate into pharmacology and the clinic. The platform consists of four integrated modules including disease modelling, manufacturing, assay development and high throughput screening. Human iPSC-derived disease models are manufactured at industry scale at the required quality for application in assays with clinically relevant read-outs suitable for high throughput screening. Together these components give an advantage to the discovery of candidates relevant to human biology before entering into the clinic.
Learn more @ DiscoverHIT Platform
Ncardia is convinced that stem cell technology will help give patients faster access to better and safer medicines by improving the drug discovery and development process. The company develops and produces highly predictive human cellular assay systems for safety and efficacy testing of drug candidates. Ncardia is based in Belgium, the Netherlands, Germany and the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.